The last decade has seen the development of a number of "local" -that is, endobronchial -treatment modalities for lung cancer, with the recognition that the endobronchial component is not only responsible for much of the symptomatology but is also accessible to direct examination and intervention. Useful techniques range from those of a principally "physical" nature such as endoscopic surgery and diathermy, laser photoresection, cryotherapy and stent placement, to treatments which may be regarded as more "biological" in nature, including photodynamic therapy and brachytherapy.
Endobronchial brachytherapy is not new; as long ago as 1922 Yankauer treated two patients by bronchoscopic placement of encapsulated radium sources. More recently the development of flexible bronchoscopy, miniature high dose rate radioisotope technology, and remote afterloading systems has enabled extremely active intrabronchial therapy to be administered in a safer, more precise, and more controlled fashion than has hitherto been possible.
The technique2 is now well known; a miniature radioactive source, welded to its drive cable, is delivered by remote control from a "safe" to a series of preplanned positions inside a catheter, placed for the purpose either within or alongside an endobronchial tumour. The catheter is placed using a standard flexible fibreoptic bronchoscope. Some series have reported laser disobliteration of the bronchial lumen before catheter placement but in our experience this has rarely been necessary. The size of the effective treatment volume is determined by the number of sequential positions of the source and by the dwell-time at each position. Typically, a sausage-shaped volume some 10 cm in length and 2 cm in diameter may be irradiated using a single catheter. If necessary two or more catheters can be used to create a more complex shape with better conformation to tumour volume, in which case computerised dose optimisation is helpful. The treatment is intense but localised, sparing the oesophagus, spinal cord, and surrounding lung from the possible effects of external beam radiotherapy. Treatment times are short with the high dose rate system, often a mere 10 minutes or so per fraction; the technique is thus suitable for outpatient or day case therapy.
The treatment is effective in achieving local tumour control. Assessment by repeat endoscopic examination indicates a delayed but progressive and often considerable reduction in tumour volume, complete endoscopic remission being quite common. Convincing relief of cough, breathlessness and, particularly, haemoptysis may be obtained with concomitant improvement in performance status,"4 but published data on more detailed quality of life assessments are sparse. Re-expansion of collapsed lung tissue occurs in about 50% of patients, a figure comparable with external beam radiotherapy. Improvement in pulmonary function, ventilation and perfusion, and exercise tolerance has been reported.
What are the current indications for brachytherapy? The localised nature of the treatment renders it suitable for the palliation of symptoms and the relief of obstructive collapse where these are caused by intrabronchial tumour. Comparative data are surprisingly rare, but there is evidence from our own series that in this group its overall efficacy is comparable with that of fractionated external beam regimens which are more demanding of patient and therapist time. No benefit can be anticipated from brachytherapy alone in patients with bulk disease causing extrinsic bronchial compression or more distant effects such as somatic pain and dysphagia. For primary palliation the duration of response is impressive, more than two thirds of patients requiring no additional radiotherapy during their lifetime. 6 The other third will require retreatment, usually with conventional radiotherapy.
Primary palliation is therefore its clearest role at the present time. It does, however, offer additional flexibility for retreatment of recurrent or residual disease,46-8 for contralateral or multiple primary tumours, combined therapy, or in patients with poor pulmonary function in whom radiation fibrosis might be expected to be poorly tolerated.
A few patients have prolonged disease-free survival even though the treatment was initially intended to be palliative. About 1% of the Manchester series falls into this category, and a number ofauthors have commented on the prolonged survival and curative potential910 where a tumour is small and capable of being totally included in the treatment volume. Accurate assessment of the volume and extent of small tumours is difficult however, even with the assistance of high resolution computed tomographic scanning. No comparative radical treatment data are available, most reports being small pilot studies or even individual case reports. The current position is that, although brachytherapy has undoubted curative potential, it is not appropriate to regard it as a primary treatment if other forms of radical treatment are practicable. There remains a small group which may be legitimately studied -those patients with technically operable or radically treatable disease who are unfit for surgery or external beam therapy for a number of reasons, the commonest being poor respiratory function.
A more frequent in patients treated with concomitant radiotherapy, in whom it is common to see dense collagenous "tracks" where the catheter has been in direct contact with normal mucosa rather than being "centred" by intrabronchial tumour. New applicator designs which incorporate spacers to keep the applicator in the centre of the bronchial lumen are currently being evaluated.'2 A major concern is the possibility of fistula formation and haemorrhage, particularly the incidence of massive haemoptysis as a terminal event following treatment. The reported incidence varies from zero to 50%, ' 
